论文部分内容阅读
目的：观察吲激酶胶囊治疗急性缺血性脑梗死的疗效。方法：１００例脑梗死病人随机分为治疗组６０例（男性３７例，女性２３例，年龄６０±ｓ１０ａ），予吲激酶胶囊４０ｍｇ，ｐｏ，ｔｉｄ；丹参注射液２０ｍＬ＋５％葡萄糖注射液５００ｍＬ，静脉滴注，ｑｄ。对照组４０例（男性２６例，女性１４例，年龄５９±８ａ），予丹参注射液２０ｍＬ＋５％葡萄糖注射剂５００ｍＬ，静脉滴注。疗程均为１０～３０ｄ。结果：治疗组总显效率８３％，对照组４３％，２组疗效比较经Ｒｉｄｉｔ分析，有显著差异（Ｐ＜０．０５）；治疗组的血液流变学指标除血细胞比容外均有显著性改变（Ｐ＜０．０５或Ｐ＜０．０１），而对照组除血沉以外改变均不明显。结论：蚓激酶加丹参治疗组疗效优于丹参对照组，蚓激酶对急性缺血性脑梗死有应用价值。
Objective: To observe the effect of indacinase capsule in the treatment of acute ischemic cerebral infarction. Methods: 100 patients with cerebral infarction were randomly divided into treatment group 60 cases (37 males and 23 females, age 60 ± s10a), indomethacin capsules 40mg, po, tid; Salvia injection 20mL +5% glucose injection 500mL, intravenous Drip, qd. Control group of 40 patients (26 males and 14 females, age 59 ± 8a), to the Danshen injection 20mL + 5% glucose injection 500mL, intravenous drip. Treatment are 10 ~ 30d. Results: The total effective rate was 83% in the treatment group and 43% in the control group. Ridit analysis was used to compare the curative effect of the two groups (P <0.05). The hemorrheological indexes of the treatment group were significant except hematocrit (P <0.05 or P <0.01), while the control group had no significant changes except for ESR. Conclusion: Lumbrokinase plus Salvia miltiorrhiza treatment group is better than Salvia miltiorrhiza control group, and Lumbrokinase has application value in acute ischemic cerebral infarction.